The DOI matches its Crossref record.
RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION
Abstract
The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental evidence suggests that RAS blockade leads to incomplete suppression of serum aldosterone levels (aldosterone escape phenomenon), offering an opportunity to consider additional treatment options to lower residual albuminuria and ameliorate kidney fi brosis.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [154]
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 201–300 of 340
Tsutamoto, T., Tanaka, T., Nishiyama, K., Yamaji, M., Kawahara, C., Fujii, M., Yamamoto, T., & Horie, M. (2009) · Hypertension Research · doi:10.1038/hr.2009.78 · Cited by 12
Viazzi, F. C., Leoncini, G., & Pontremoli, R. (2013) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-013-0027-y · Cited by 13
Aldosterone and cardiovascular remodelling: focus on myocardial failure
Shieh, F. K., Kotlyar, E., & Sam, F. (2004) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2004.005 · Cited by 12
Aldosterone blockade in heart failure
Struthers, A. D. (2004) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2004.021 · Cited by 12
Dieterich, H. A., Wendt, C. D., & Saborowski, F. (2005) · Human Physiology · doi:10.1007/s10747-005-0119-8 · Cited by 11
Imaging the renin-angiotensin-aldosterone system in the heart
Shirani, J., Loredo, M. L., Eckelman, W. C., Jagoda, E. M., & Dilsizian, V. (2005) · Current Heart Failure Reports · doi:10.1007/s11897-005-0013-3 · Cited by 11
Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies
Papademetriou, V., Tsioufis, C. P., Gradman, A. H., & Punzi, H. A. (2011) · International Journal of Hypertension · doi:10.4061/2011/438198 · Cited by 11
Sumino, H., Ichikawa, S., Kasama, S., Takahashi, T., Kumakura, H., Takayama, Y., Kanda, T., Murakami, M., & Kurabayashi, M. (2009) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2009.00562.x · Cited by 11
Kidney and Blood Pressure Regulation
Suzuki, H., & Saruta, T. (2004) · Contributions to nephrology · doi:10.1159/isbn.978-3-318-01086-2 · Cited by 11
Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action
Trubitsyna, N. P., Zaytseva, N. V., Severina, A. S., & Шамхалова, М. Ш. (2022) · Diabetes Mellitus · doi:10.14341/dm12944 · Cited by 12
Jansen, P. M., Hofland, J., van den Meiracker, A. H., de Jong, F. H., & Danser, A. J. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312438792 · Cited by 10
Aldosterone receptor antagonists: Biology and novel therapeutic applications
Magni, P., & Motta, M. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0012-5 · Cited by 10
Nochioka, K., Sakata, Y., & Shimokawa, H. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_179 · Cited by 10
Homma, K., Hayashi, K., Kanda, T., Yoshioka, K., Takamatsu, I., Tatematsu, S., Kumagai, H., Wakino, S., & Saruta, T. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001761 · Cited by 10
Aldosterone, a New Appreciation of Its Role in Heart Failure
Cha, A. J., Malecha, S. E., & Judge, K. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.13.1107.35023 · Cited by 10
Berecek, K. H., Farag, A., Bahtiyar, G., Rothman, J., & McFarlane, S. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0071-z · Cited by 10
Lopez, A.-G., Louiset, E., & Lefèbvre, H. (2022) · Hypertension Research · doi:10.1038/s41440-022-01009-9 · Cited by 10
Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome
Pitt, B. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04117 · Cited by 9
Maiolino, G., Azzolini, M., & Rossi, G. P. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00003 · Cited by 9
Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade
Pitt, B., & Bakris, G. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad299 · Cited by 9
Aggarwal, D., & Singh, G. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01759-3 · Cited by 9
Myxomatous Degenerative Mitral Valve Disease: An Update
Disatian, S. (2010) · The Thai Journal of Veterinary Medicine · doi:10.56808/2985-1130.2218 · Cited by 9
Shah, S. R., & Winchester, D. E. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1479252 · Cited by 9
Drug Treatment of Heart Failure in Children: Gaps and Opportunities
Weisert, M., Su, J. A., Menteer, J., Shaddy, R. E., & Kantor, P. F. (2022) · Pediatric Drugs · doi:10.1007/s40272-021-00485-9 · Cited by 8
Pasquale, P. D., Cannizzaro, S., Scandurra, A., Giubilato, A., Scalzo, S., & Paterna, S. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1012754514127 · Cited by 8
An in vivo role of bone morphogenetic protein-6 in aldosterone production by rat adrenal gland
Matsumoto, Y., Otsuka, F., Inagaki, K., Tsukamoto, N., Takano-Narazaki, M., Miyoshi, T., Nakamura, E., Ogura-Ochi, K., Takeda, M., & Makino, H. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.04.004 · Cited by 8
Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist
Verma, A., & Solomon, S. D. (2007) · Current Heart Failure Reports · doi:10.1007/s11897-007-0011-8 · Cited by 8
Pasquale, P. D., Alessi, V., Barberi, O., Scandurra, A., Bucca, V., Maringhini, G., Scalzo, S., & Paterna, S. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(00)00425-3 · Cited by 8
Aldosterone in Chronic Kidney Disease
Polenus, P., Đuran, A., & Karanović, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092081 · Cited by 7
Chi, J., Uzui, H., Guo, H. Y., Ueda, T., & Lee, J. D. (2014) · Genetics and Molecular Research · doi:10.4238/2014.january.24.4 · Cited by 7
Spironolactone in the Treatment of Congestive Heart Failure
Lloyd, S. J., & Mauro, V. F. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.10104 · Cited by 7
Takaya, J., Matsusaka, T., Katori, H., Tamura, M., Miyazaki, Y., Homma, T., & Ichikawa, I. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.12.0737 · Cited by 7
Cardiovascular effects of aldosterone
Murin, J. (2005) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03656699 · Cited by 7
The Role of Aldosterone Blockers in the Management of Chronic Heart Failure
Coca, S. G., & Perazella, M. A. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200510000-00005 · Cited by 7
Aldosterone breakthrough from a pharmacological perspective
Alfie, J. (2023) · Hypertension Research · doi:10.1038/s41440-023-01204-2 · Cited by 7
Aldosterone and refractory hypertension
Nyirenda, M., & Padfield, P. L. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32814db831 · Cited by 6
Upadhyay, A., & Haider, L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0036 · Cited by 6
Sumi, K., Ohkura, T., Yamamoto, N., Fujioka, Y., Matsuzawa, K., Izawa, S., Shiochi, H., Kinoshita, H., Ohkura, H., Kato, M., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0116-0 · Cited by 6
Influence of Salt Intake on Target Organ Damages in Treated Hypertensive Patients
Ohta, Y., Tsuchihashi, T., & Kiyohara, K. (2012) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2011.618199 · Cited by 6
Aldosterone receptor antagonists: Biology and novel therapeutical applications
Magni, P., & Motta, M. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03347366 · Cited by 6
Aldosterone Receptor Antagonism in Heart Failure
Jennings, D. L., Kalus, J. S., & O’Dell, K. M. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.8.1126 · Cited by 6
Cao, J.-Y., Ling, L., Ni, W., Guo, H., & Yang, M. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1902821 · Cited by 5
Sawai, T., Dohi, K., Fujimoto, N., Okubo, S., Isaka, N., Ichikawa, T., Makino, K., Okamoto, S., Koyabu, S., Kitamura, T., et al. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13054 · Cited by 4
Hanazawa, T., Obara, T., Ogasawara, K., Shinki, T., Katada, S., Inoue, R., Metoki, H., Asayama, K., Kikuya, M., Ohkubo, T., et al. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2010.531844 · Cited by 5
Future and Novel Compounds in the Treatment of Diabetic Nephropathy
Idzerda, N. M. A., Pena, M. J., de Zeeuw, D., & Heerspink, H. J. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_29 · Cited by 5
Aldosterone antagonists for people with chronic kidney disease requiring dialysis
Hasegawa, T., Nishiwaki, H., Ota, E., Levack, W., & Noma, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013109 · Cited by 5
Hisatake, S., Kiuchi, S., Kabuki, T., Oka, T., Dobashi, S., Fujii, T., & Ikeda, T. (2020) · Bioscience Reports · doi:10.1042/bsr20192701 · Cited by 5
Heart Failure due to Left Ventricular Systolic Dysfunction
Lampert, B. C., Dyke, D. B. S., & Koelling, T. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-28328-5_13 · Cited by 6
Jungmann, E., Störger, H., Althoff, P.-H., Hadler, D., Fassbinder, W., Bussmann, W. ‐., Kaltenbach, M., & Schöffling, K. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00635699 · Cited by 5
Current and novel pharmacologic approaches in advanced heart failure
O’Connor, C. M., Gattis, W. A., & Swedberg, K. B. (1999) · Heart & Lung · doi:10.1016/s0147-9563(99)70069-5 · Cited by 5
Appropriate drug therapy for improving outcomes in diabetic nephropathy
Toto, R. D. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0126-y · Cited by 5
Aldosterone Receptor Blockade in the Management of Heart Failure
Palmieri, E. A., Biondi, B., & Fazio, S. (2002) · Heart Failure Reviews · doi:10.1023/a:1015336831407 · Cited by 5
Pitt, B., & Byrd, J. B. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa765 · Cited by 5
Quadruple therapy in heart failure: Why, when, and in whom?
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103352 · Cited by 5
Jansen, P. M., Verdonk, K., Imholz, B. P. M., Danser, A. H. J., & van den Meiracker, A. H. (2011) · International Journal of Hypertension · doi:10.4061/2011/368140 · Cited by 4
Zhai, Y., Li, J., Peng, L., Lu, G., & Gao, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315061 · Cited by 4
Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy
Koubský, K. (2024) · Physiological Research · doi:10.33549/physiolres.935438 · Cited by 7
Cook, C. S., & Zhang, L. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10124 · Cited by 4
Mineralcorticoid Antagonists in Heart Failure
D’Elia, E., & Krum, H. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.07.003 · Cited by 4
Treatment Of Heart Failure In A Teaching Hospital In Ghana, West Africa
(2007) · The Internet Journal of Third World Medicine · doi:10.5580/17c2 · Cited by 4
The Renin–Angiotensin–Aldosterone System and the Kidney
Ko, B. S., & Bakris, G. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00002-7 · Cited by 5
Potassium supplements or potassium‐sparing agents
Persson, S. (1984) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1984.tb03642.x · Cited by 4
Non-antiarrhythmic medications for atrial fibrillation: From bench to clinical practice
Guglin, M. E., Garcia, M., Yarnoz, M. J., & Curtis, A. B. (2008) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-008-9204-7 · Cited by 4
Treatment of patients with heart failure and preserved ejection fraction
Deswal, A. M., & Bozkurt, B. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0044-7 · Cited by 4
Ruilope, L. M., & Segura, J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.522992 · Cited by 4
Christ, M., Ludwig, N., & Maisch, B. (2002) · Herz · doi:10.1007/s00059-002-2352-0 · Cited by 4
Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction
Paul, S. C., & Page, R. L., II (2015) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000284 · Cited by 3
Aldosterone Receptor Antagonist and Heart Failure Following Acute Myocardial Infarction
Verma, A. K., Bulwer, B. E., Dhawan, I., Yeh, H., & Hung, C. (2010) · Zhōnghuá mínguó xīnzàngxué huì zázhì · Cited by 3
Harasawa, S., Otsuka, Y., Okubo, K., Koike, M., Fujita, H., Kushiro, T., Nagao, K., & Hirayama, A. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01164.x · Cited by 3
Cook, C. S., & Zhang, L. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10053 · Cited by 3
The Use of Aldosterone Receptor Blockers in the Treatment of Hypertension
Weinberger, M. H. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03057.x · Cited by 3
Reduction of blood pressure in patients with treatment-resistant hypertension
Acelajado, M. C., Calhoun, D. A., & Oparil, S. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903379552 · Cited by 3
Kawada, N., Isaka, Y., Kitamura, H., Rakugi, H., & Moriyama, T. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314532509 · Cited by 3
Stellenwert der aldosteronantagonistischen Therapie
Christ, M., Grimm, W., & Maisch, B. (2004) · Der Internist · doi:10.1007/s00108-003-1087-1 · Cited by 3
Role of Aldosterone Blockade in the Management of Hypertension and Cardiovascular Disease
Epstein, M. M. (2004) · KARGER eBooks · doi:10.1159/000078714 · Cited by 3
Emerging therapies for heart failure
Rudolph, A. E., & McMahon, E. G. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.247 · Cited by 3
Pitt, B. (1994) · Cardiology Clinics · doi:10.1016/s0733-8651(18)30129-2 · Cited by 3
On the Need to Reissue Renin-Angiotensin-Aldosterone System Suppression in Chronic Kidney Disease
Ruilope, L. M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0133-5 · Cited by 2
Otani, H., Otsuka, F., & Makino, H. (2010) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.122.27 · Cited by 2
Aldosterone - the future challenge in cardiovascular disease?
Connell, J. (2004) · Cited by 2
Review: Aldosterone — the future challenge in cardiovascular disease?
Connell, J. (2004) · The British Journal of Diabetes · doi:10.1177/14746514040040060201 · Cited by 2
Aldosterone breakthrough does not alter central hemodynamics
Beenken, A., & Bomback, A. S. (2017) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320317735002 · Cited by 2
Review: Role of the selective aldosterone receptor blockers in arterial hypertension
Sierra, C., & Ruilope, L. M. (2004) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2004.002 · Cited by 2
Richart, T., Staessen, J. A., & ger, W. B. (2007) · Drugs · doi:10.2165/00003495-200767090-00009 · Cited by 2
Self-citationAzpitarte, J. (2000) · Medicina Clínica · doi:10.1016/s0025-7753(00)71358-3 · Cited by 2
Blockade of the renin–angiotensin system for the primary prevention of diabetic nephropathy
Thomas, M. C., & MacGinley, R. (2011) · Diabetes Management · doi:10.2217/dmt.11.69 · Cited by 1
Badheka, A. O., Tuliani, T. A., Rathod, A. D., Kizilbash, M. A., Bharadwaj, A. S., & Afonso, L. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.06.019 · Cited by 1
How to best to counteract the enemies? By blocking neurohormonal activation
Soler‐Soler, J. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90089-1 · Cited by 1
Mineralocorticoid Receptor Antagonists
McMahon, E. G. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50160-5 · Cited by 1
Heggermont, W., Goethals, M. A., Dierckx, R., Verstreken, S., Bartúnek, J., & Vanderheyden, M. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9583-2 · Cited by 1
Management of resistant hypertension
Holaj, R. (2011) · Cor et Vasa · doi:10.33678/cor.2011.108 · Cited by 1
Goldman, J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_7 · Cited by 1
Inhibition of the Renin-Angiotensin-Aldosterone System
Koelling, T. M., Bradley, D., Dyke, S., & Cody, R. J. (2005) · doi:10.1007/978-1-4757-4558-0_11 · Cited by 1
Hara, Y., Hamada, M., Shigematsu, Y., Ohtsuka, T., & Hiwada, K. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00420.x · Cited by 1
Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
Coca, S. G., & Perazella, M. A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.497 · Cited by 1
[Antialdosteronic therapy in mild chronic heart failure: from AREA IN-CHF to EMPHASIS-HF].
Boccanelli, A. (2010) · PubMed · Cited by 1
Sierra, C., & Ruilope, L. M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.987 · Cited by 1
(1982) · New England Journal of Medicine · doi:10.1056/nejm198207013070113 · Cited by 1
Inhibitors of the Renin-Angiotensin System as Antihypertensive Agents
Staessen, J. A., Fagard, R. H., Lijnen, P., & Amery, A. (1982) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-7476-0_53 · Cited by 1
Self-citation
Metadata
- Authors
- STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A.
- ORCID
- STAESSEN, J.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1981-12-01
- Volume
- 91
- Issue
- 3
- Pages
- 457-465
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W1971680322
- Cited by
- 339
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 10 · 2014: 20 · 2013: 7 · 2012: 14
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- aldosterone, captopril, ACE inhibitors, hypertension, plasma renin activity, renin-angiotensin system, long-term drug therapy, hypotension
- MeSH terms
- Adult, Aldosterone, Angiotensin II, Captopril, Depression, Chemical, Female, Humans, Hypertension, Male, Middle Aged, Proline, Renin, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review